Lixisenatide is effective and well tolerated in patients with type 2 diabetes mellitus and renal impairment

被引：0
|
作者：
Hanefeld, M. [1 ]
Ambos, A. [2 ]
Arteaga, J. [3 ]
Leiter, L. A. [4 ]
Marchesini, G. [5 ]
Nikonova, E. [6 ]
Shestakova, M. [7 ]
Stager, W. [8 ]
Tambascia, M. [9 ]
Gomez Huelgas, R. [10 ]
机构：
[1] GWT TUD GmbH, Study Ctr Prof Hanefeld, Dresden, Germany
[2] North Estonia Med Ctr, Tallinn, Estonia
[3] Univ Nacl Colombia, Sch Med, Bogota, Colombia
[4] Univ Toronto, St Michaels Hosp, Toronto, ON M5S 1A1, Canada
[5] Univ Bologna, I-40126 Bologna, Italy
[6] Sanofi, Diabet Div, Global Med Afairs, Bridgewater, MA USA
[7] Endocrinol Res Ctr, Moscow, Russia
[8] Sanofi, Diabet Div, Bridgewater, MA USA
[9] Univ Estadual Campinas, Campinas, SP, Brazil
[10] Univ Reg Hosp, Malaga, Spain
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
841
引用
收藏
页码：S341 / S342
页数：2
相关论文
共 50 条
  • [1] Lixisenatide Is Effective and Well Tolerated in Patients with Type 2 Diabetes Mellitus and Renal Impairment
    Gomez-Huelgas, Ricardo
    Ambos, Anu
    Arteaga, Juan M.
    Leiter, Lawrence A.
    Marchesini, Giulio
    Nikonova, Elena
    Shestakova, Marina
    Stager, William
    Tambascia, Marcos
    Hanefeld, Markolf
    DIABETES, 2014, 63 : A254 - A255
  • [2] Repaglinide is well tolerated and effective in Type 2 diabetes complicated by renal impairment
    Koselj, M
    Gali, M
    Sieber, J
    Dieken, ML
    Hasslacher, C
    DIABETOLOGIA, 2001, 44 : A36 - A36
  • [3] Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
    Nowicki, M.
    Rychlik, I.
    Haller, H.
    Warren, M. L.
    Suchower, L.
    Gause-Nilsson, I.
    DIABETES OBESITY & METABOLISM, 2011, 13 (06): : 523 - 532
  • [4] Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
    Hanefeld, Markolf
    Arteaga, Juan M.
    Leiter, Lawrence A.
    Marchesini, Giulio
    Nikonova, Elena
    Shestakova, Marina
    Stager, William
    Gomez-Huelgas, Ricardo
    DIABETES OBESITY & METABOLISM, 2017, 19 (11): : 1594 - 1601
  • [5] Novartis drug Vildagliptin shown to be well-tolerated and effective in patients with type 2 diabetes and moderate or severe renal impairment
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2011, 13 (11): : 1060 - 1060
  • [6] Saxagliptin Improves Glycemic Control and Is Well Tolerated in Patients with Type 2 Diabetes Mellitus (T2DM) and Renal Impairment Compared with Placebo
    Owens, David R.
    Swallow, Ros
    Jones, Peter
    Dugi, Klaus A.
    Woerle, Hans-Juergen
    DIABETES, 2010, 59 : A149 - A150
  • [7] Lixisenatide for type 2 diabetes mellitus
    Christensen, Mikkel
    Knop, Filip K.
    Vilsboll, Tina
    Holst, Jens J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (04) : 549 - 557
  • [8] Vildagliptin in patients with type 2 diabetes mellitus and renal impairment
    Groop, Per-Henrik
    Dongre, Neelesh
    Kothny, Wolfgang
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 (02) : E12 - E13
  • [9] Rosiglitazone is effective and well tolerated in patients ≥65 years with type 2 diabetes
    Beebe, K
    Patel, J
    DIABETES, 1999, 48 : A111 - A111
  • [10] Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus
    Niedermier, Valerie
    Springer, Sydney
    AMERICAN FAMILY PHYSICIAN, 2017, 96 (04) : 257 - 258
12345